荧光素钠辅助术中样本验证以提高立体定向脑活检诊断率:迈向新标准治疗?
研究纳入2013年5月至2021年6月共103例无框架神经导航立体定向脑活检病例,比较46例标准非辅助活检与57例荧光素钠辅助活检。荧光素钠辅助组诊断率100%(95%CI 93.73%-100%)显著高于标准组89.13%(95%CI 80.14%-98.13%)(p=0.0157),平均手术时间、术中及术后并发症无显著差异。
要点
- 荧光素钠辅助立体定向活检诊断率100%,显著高于标准活检的89.13%(p=0.0157)。
- 两组平均手术时间、术中并发症、术后并发症均无显著差异。
- 作者提出荧光素钠辅助活检应作为对比增强病例的标准治疗。
核心结论
- 与标准非辅助立体定向活检相比,荧光素钠辅助活检诊断率显著更高,手术时间和并发症发生率相似。
- 荧光素钠使用简便、诊断谱广、成本低,优于其他荧光团。
- 本研究强化了文献中支持常规使用荧光素钠辅助活检的有限数据。
- 所提流程建议荧光素钠辅助活检应作为对比增强病例的标准治疗,术中组织病理学应限于非增强病例,应避免标准非辅助活检。
- 未来前瞻性多中心研究将有助于进一步验证本研究发现。
研究设计与样本
- 回顾性收集2017年前数据、此后前瞻性收集,纳入作者中心2013年5月至2021年6月连续103例无框架神经导航立体定向脑活检病例。
- 46例接受标准非辅助立体定向活检(nSB),57例接受荧光素钠辅助立体定向活检(fSB)。
- 比较两组诊断率、手术时间和并发症发生率,并标准化fSB手术技术、开发术中荧光发现的新分类系统。
主要发现
- fSB组诊断率100%(95%CI 93.73%-100%)显著高于nSB组89.13%(95%CI 80.14%-98.13%)(p=0.0157)。
- 两组平均手术时间无统计学显著差异(p=0.7104)。
- 两组术中并发症无统计学显著差异(p=0.999)。
- 两组术后并发症无统计学显著差异(p=0.5083)。
临床怎么用
- 作者提出所提流程建议fSB应作为对比增强病例的标准治疗,术中组织病理学应限于非增强病例,应避免nSB。
- 作者认为荧光素钠使用简便、诊断谱广、成本低,优于其他荧光团。
- 作者认为本研究强化了支持常规使用fSB的有限文献数据。
局限性
- 2017年前数据为回顾性收集。
- 作者指出未来前瞻性多中心研究将有助于进一步验证本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with contraindication to open resection, histological diagnosis is obtained through a stereotactic biopsy (SB). Missed diagnoses and sampling errors are important limitations of SB; therefore, various ways have been proposed to increase the diagnostic yield (DY). Intraoperative histopathology can obtain a DY exceeding 98% but with several drawbacks, namely prolonged operative times and logistic concerns. The objective of this study was to evaluate whether intraoperative validation of samples with fluorescein sodium can obtain a high DY with the same ease of use as standard SB. METHODS: One hundred three consecutive cases of frameless neuronavigated SB performed at the authors' center from May 2013 to June 2021 were included. Two groups were compared: 46 patients underwent standard nonassisted SB (nSB), and 57 patients underwent fluorescein sodium-assisted SB (fSB). Data were collected retrospectively before 2017 and prospectively thereafter. DY, operative time, and rate of complications were compared between the two groups. The surgical technique for fSB was standardized, and a novel classification system for intraoperative fluorescence findings was developed. RESULTS: Statistically significant differences between the two groups were identified. The DY of the fSB group (100%, 95% CI 93.73%-100%) was significantly greater than that of the nSB group (89.13%, 95% CI 80.14%-98.13%) (p = 0.0157). No statistically significant differences were observed in terms of mean operative time (p = 0.7104), intraoperative complications (p = 0.999), or postoperative complications (p = 0.5083). CONCLUSIONS: Compared with standard nSB, fSB showed a significantly higher DY and similar surgical time and rate of complications. The ease of use, wide diagnostic spectrum, and low cost make fluorescein sodium preferable to other fluorophores. The present study strengthens the limited data in the literature indicating routine use of fSB. The proposed workflow suggests that fSB should be the standard of care for contrast-enhanced cases. Intraoperative histopathology should be limited to nonenhancing cases, and nSB should be avoided. Future prospective multicenter studies will be useful for further validation of our findings.
引用
- Bianco A, Del Maestro M, Fanti A, et al. Use of fluorescein sodium-assisted intraoperative sample validation to maximize the diagnostic yield of stereotactic brain biopsy: progress toward a new standard of care? J Neurosurg. 2022. PMID: 36303472. doi:10.3171/2022.4.JNS212954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。